Topics
Acute liver injury and Acute liver failure (9)
Alcohol-related liver disease (31)
Autoimmune liver disease (28)
Cholestatic liver disease (7)
Liver fibrosis, cirrhosis, and portal hypertension (126)
Benign liver tumors and cystic disease of liver (17)
Drug induced liver injury (9)
Gallbladder disease (0)
Genetic liver disease (0)
Hepatic involvement of systemic disease (2)
Hepatic neoplasm (273)
Infectious liver disease (7)
Liver development and regeneration (2)
Liver disease in pregnancy (0)
Liver Transplantation (27)
Steatotic liver disease (206)
Nutritional and Metabolic liver disease (4)
Microbiome (2)
Viral hepatitis (265)
Vascular disorders of liver (4)
Artificial intelligence, epidemiology, methodology, or others (36)
COVID-19 (10)
Erratum
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee
Clin Mol Hepatol. 2025;31(2):669-670. Published online February 27, 2025
View: 1221
Download: 46
Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021
Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang
Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025